As announced by Exor (“Exor” or the “Company”) on 29 July 2022, the Company’s board of directors has approved the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, a regulated market organised and managed by Euronext Amsterdam N.V., which hosts some of Europe’s leading corporations.
Exor (“Exor” or the “Company”) announces that its Board of Directors approved today the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, which hosts some of Europe’s leading corporations.
Exor N.V. has closed today the agreement to acquire a 10% shareholding of Institut Mérieux, the privately held global healthcare holding of the Mérieux family. A consideration of €278 million, corresponding to one third of the €833 million total investment, was paid today by way of a reserved capital increase, while the remaining amount is expected to be contributed within the next 12 months.
As part of the partnership sealed with the Mérieux family, John Elkann and Benoît Ribadeau-Dumas have joined Institut Mérieux’s Board of Directors.
Exor announces that it has completed the sale of PartnerRe, the global reinsurer, to Covéa for a total cash consideration of $9.3 billion (approximately €8.6 billion1). This is based on a consolidated common shareholders’ equity value of $7.3 billion as at 31 December 2021.
The acquisition of PartnerRe by Covéa reinforces PartnerRe’s development as a great company in its industry thanks to a significant increase in the scale and capital strength that membership of a larger financial institution brings, and the value that it represents for its clients.
Institut Mérieux (“Institut Mérieux” or “the Company”), the privately held global healthcare holding of the Mérieux family, and Exor N.V.
Following receipt of the required regulatory approvals, the investment announced on April 22 has been closed: Exor N.V. ("Exor") has today acquired a 45% shareholding in Lifenet S.r.l., an Italian company active in the healthcare sector, particularly in the management of hospitals and outpatient clinics.
The transaction entails a total investment by Exor of €67 million.
Exor N.V. (“Exor” or “the Company”), the diversified holding company controlled by the Agnelli family, announces that meeting today the Company’s Board of Directors resolved to separate the roles of Chairman and Chief Executive Officer.
EXOR N.V. (“Exor” or the “Company”) announces that all the resolutions proposed by the Board of Directors to the Annual General Meeting of Shareholders (the “AGM”) held virtually today were approved.
Exor N.V. (“Exor”), a leading diversified holding company controlled by the Agnelli family, has signed an agreement to acquire a 45% shareholding in Lifenet S.r.l. (“Lifenet Healthcare” or “the Company”), an Italian company active in the healthcare sector, particularly in the management of hospitals and outpatient clinics. The transaction, which will be executed principally via a capital increase reserved for Exor and the concurrent acquisition of shares owned by Invin S.r.l., the company that controls Lifenet, entails a total investment by Exor of €67 million.
Exor announces the launch of an Italy-focused seed initiative to support the country’s most promising entrepreneurs building the next generation of great companies. Exor Seeds (early stage venture arm of Exor) will invest in pre-seed and seed stage startups offering a €150K investment with an efficient diligence process, founder-friendly terms, and no board seat.